摘要
目的探讨双环醇治疗非酒精性脂肪性肝病(NAFLD)患者的有效性。方法从PubMed、Medline、Embase英文数据库以及万方数据库、维普中文网、知网中文数据库检索有关双环醇和NAFLD的相关文献,筛选文献后并提取数据,时限设定为建库至2019年12月,采用Cochrane偏倚风险表的评价文献的质量,采用RevMan5.3软件进行统计学分析。结果共纳入8篇文献,共873例患者,其中试验组446例,对照组427例,在双环醇治疗2个月至6个月后,NAFLD患者血清ALT明显下降(WMD=-13.19,95%CI:-22.0~-4.37,P=0.003);在治疗24周至6个月后,NAFLD患者血清TG明显下降(WMD=-0.38,95%CI:-0.74~-0.02,P=0.04);在治疗24周至6个月后,NAFLD患者血清TC明显下降(WMD=-0.21,95%CI:-0.37~-0.06,P=0.007)。结论双环醇可有效降低NAFLD患者血清中ALT、TG、TC水平。
Objective To investigate the efficacy of bicyclol in the treatment of transaminase and lipid in patients with nonalcoholic fatty liver disease(NAFLD),and to search for related literature for meta analysis.Methods From PubMed,MEDLINE,EMBASE English database,Wanfang database,VIP Chinese network and HowNet Chinese database,the relevant literatures of bicyclol and NAFLD were searched.After literature screening and data extraction,the time limit was set as from the establishment of the database to December 2019.Cochrane bias risk table was used to evaluate the quality of literature,and Revman 5.3 software was used for statistical analysis.Results In this study,8 articles were included,and 873 patients were enrolled,446 in the experimental group and 427 in the control group.After 2-6 months of bicyclol treatment,serum ALT of NAFLD patients decreased significantly[WMD=-13.19,95%CI:-22.0~-4.37,P=0.003];After 2-6 months of treatment,the serum TG of NAFLD patients decreased significantly[WMD=-0.38,95%CI:-0.74~-0.02,P=0.04];After 2-6 months of treatment,the serum TC of NAFLD patients decreased significantly[WMD=-0.21,95%CI:-0.37~-0.06,P=0.007].Conclusion Bicyclol can effectively reduce the levels of ALT,TG and TC in serum of patients with non-alcoholic fatty liver disease.
作者
李贲
纪世博
赵莹莹
程丹颖
李炜
欧蔚妮
邢卉春
LI Ben;JI Shi-bo;ZHAO Ying-ying;CHENG Dan-ying;LI Wei;OU Wei-ni;XING Hui-chun(Central of Liver Diseases Division 3,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China)
出处
《肝脏》
2021年第4期424-428,434,共6页
Chinese Hepatology
基金
北京市医院管理局扬帆计划(XMLX201837)
十三五艾滋病和病毒性肝炎等重大传染病防治(2018ZX10302206-003-006)
北京市医院管理局消化内科学科协同发展中心项目(XXT26)
首都卫生发展科研专项(首发2020-1-2171)。
